AFMD

Affimed N.V. [AFMD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AFMD Stock Summary

Top 10 Correlated Stocks

AFMD


In the News

06:30 10 Jun 2023 AFMD

Affimed to Present at the 2023 Jefferies Healthcare Conference

HEIDELBERG, Germany, May 30, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. Eastern Daylight Time / 14:30 Central European Time.

12:36 10 Jun 2023 AFMD

Affimed N.V. (AFMD) Q1 2023 Earnings Call Transcript

Affimed N.V. (NASDAQ:AFMD ) Q1 2023 Earnings Conference Call May 23, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Arndt Schottelius - Chief Scientific Officer Conference Call Participants Maurice Raycroft - Jefferies Li Watsek - Cantor Fitzgerald Srikripa Devarakonda - Truist Securities Bradley Canino - Stifel Yale Jen - Laidlaw Yanan Zhu - Wells Fargo Securities Operator Good day, everyone and welcome to Affimed's First Quarter 2023 Earnings and Corporate Update Call.

08:53 10 Jun 2023 AFMD

Affimed N.V. (AFMD) Reports Q1 Loss, Lags Revenue Estimates

Affimed N.V. (AFMD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.22.

06:30 10 Jun 2023 AFMD

Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023

HEIDELBERG, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2023 results and corporate update on Tuesday, May 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.

09:08 10 Jun 2023 AFMD

Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022.

06:30 10 Jun 2023 AFMD

Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023

HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.

06:30 10 Jun 2023 AFMD

Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference

HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 28, 2023, at 8:30 a.m. EST / 14:30 CET.

06:30 10 Jun 2023 AFMD

Affimed to Present at the SVB Securities 2023 Global Biopharma Conference

HEIDELBERG, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will present at the SVB Securities 2023 Global Biopharma Conference on Tuesday, February 14, 2023 at 2:20 p.m. EST / 20:20 CET.

01:58 10 Jun 2023 AFMD

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

11:18 10 Jun 2023 AFMD

Here's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks

Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

AFMD Financial details

Company Rating
Buy
Market Cap
131.07M
Income
-99.64M
Revenue
37.86M
Book val./share
0.84
Cash/share
1.04
Dividend
-
Dividend %
-
Employees
219
Optionable
No
Shortable
Yes
Earnings
09 Aug 2023
P/E
-0.97
Forward P/E
-
PEG
-0.23
P/S
2.55
P/B
0.77
P/C
0.69
P/FCF
-0.87
Quick Ratio
5.08
Current Ratio
5.21
Debt / Equity
0.34
LT Debt / Equity
0.08
-
-
EPS (TTM)
-0.68
EPS next Y
-
EPS next Q
-
EPS this Y
25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
13.4%
Revenue last 5Y
11.74%
Revenue Q/Q
-59.58%
EPS Q/Q
-19.23%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
39.64%
Inst Trans
-15.22%
ROA
-59%
ROE
-61%
ROC
-0.75%
Gross Margin
100%
Oper. Margin
-271%
Profit Margin
-263%
Payout
-
Shs Outstand
149.34M
Shs Float
125.56M
-
-
-
-
Target Price
-
52W Range
0.55-3.4
52W High
-
52W Low
-
RSI
36
Rel Volume
1.58
Avg Volume
750.01K
Volume
1.18M
Perf Week
-15.75%
Perf Month
-20.09%
Perf Quarter
-35.79%
Perf Half Y
-63.86%
-
-
-
-
Beta
2.51795
-
-
Volatility
0.06%, 0.09%
Prev Close
3.39%
Price
0.7192
Change
-6.35%

AFMD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0.390.330.340.340.29
Net income per share
-0.32-0.5-0.5-0.48-0.6
Operating cash flow per share
0.82-0.45-0.23-0.72-0.74
Free cash flow per share
0.81-0.48-0.24-0.76-0.74
Cash per share
1.81.621.761.651.34
Book value per share
0.660.60.861.141.07
Tangible book value per share
0.660.60.841.121.07
Share holders equity per share
0.660.60.861.141.07
Interest debt per share
0.090.060.020.160.14
Market cap
164.4M157.14M399.19M582.47M165.33M
Enterprise value
74.34M65.09M253.63M403.53M-6.76M
P/E ratio
-8.44-4.86-9.65-10.13-1.92
Price to sales ratio
6.937.3514.0814.434
POCF ratio
3.33-5.41-20.58-6.73-1.58
PFCF ratio
3.37-5.15-20.12-6.44-1.57
P/B Ratio
4.14.065.544.281.08
PTB ratio
4.14.065.544.281.08
EV to sales
3.133.048.9410-0.16
Enterprise value over EBITDA
-4.08-2.1-7.41-6.30.08
EV to operating cash flow
1.5-2.24-13.07-4.660.06
EV to free cash flow
1.53-2.13-12.78-4.460.06
Earnings yield
-0.12-0.21-0.1-0.1-0.52
Free cash flow yield
0.3-0.19-0.05-0.16-0.64
Debt to equity
1.91.911.440.660.31
Debt to assets
0.650.660.590.40.24
Net debt to EBITDA
4.942.964.252.81.99
Current ratio
3.013.012.253.25.66
Interest coverage
-23.06-67.03-365.45-89.93-54.06
Income quality
-2.540.90.471.511.22
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.410.480.480.60.78
Research and developement to revenue
1.482.051.762.022.39
Intangibles to total assets
000.010.010
Capex to operating cash flow
-0.010.050.020.040.01
Capex to revenue
-0.03-0.07-0.02-0.1-0.02
Capex to depreciation
-1.79-1.63-0.39-2.89-0.24
Stock based compensation to revenue
0.090.120.120.290.46
Graham number
2.192.613.13.513.82
ROIC
0.240.360.270.340.44
Return on tangible assets
-0.17-0.29-0.24-0.26-0.43
Graham Net
0.560.490.540.941.02
Working capital
74.04M70.73M83.77M141.85M161.42M
Tangible asset value
40.07M38.53M70.28M134.34M152.86M
Net current asset value
34.83M32.22M47.07M117.21M148.47M
Invested capital
0.120.080.020.140.12
Average receivables
1.27M1.46M1.96M3.62M3.75M
Average payables
6.8M10.05M11.03M15.13M18.97M
Average inventory
250.5K278K271K333.5K524.5K
Days sales outstanding
21.9825.2931.3943.4823.8
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
16.6114.4311.638.3915.33
Payables turnover
00000
Inventory turnover
00000
ROE
-0.49-0.84-0.57-0.42-0.56
Capex per share
-0.01-0.02-0.01-0.030

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric History 2022-03-312022-06-302022-09-302022-12-31 2023-03-31
Revenue per share
0.060.050.10.080.03
Net income per share
-0.14-0.12-0.09-0.26-0.21
Operating cash flow per share
-0.23-0.18-0.13-0.22-0.22
Free cash flow per share
-0.23-0.18-0.13-0.22-0.22
Cash per share
1.381.611.491.341.04
Book value per share
0.951.311.211.070.84
Tangible book value per share
0.951.311.211.070.84
Share holders equity per share
0.951.311.211.070.84
Interest debt per share
0.150.130.130.130.12
Market cap
488.2M391.28M312.97M165.33M102.11M
Enterprise value
336.99M172.84M108.81M-6.76M-37.02M
P/E ratio
-7.32-5.7-5.68-1.13-0.8
Price to sales ratio
60.9853.5921.0214.8222.64
POCF ratio
-17.18-14.77-16.45-5.34-3.07
PFCF ratio
-17.11-14.73-16.36-5.27-3.07
P/B Ratio
4.162.031.731.080.82
PTB ratio
4.162.031.731.080.82
EV to sales
42.0923.677.31-0.61-8.21
Enterprise value over EBITDA
-20-8.1-5.810.241.21
EV to operating cash flow
-11.86-6.53-5.720.221.11
EV to free cash flow
-11.81-6.5-5.690.221.11
Earnings yield
-0.03-0.04-0.04-0.22-0.31
Free cash flow yield
-0.06-0.07-0.06-0.19-0.33
Debt to equity
0.650.350.310.310.34
Debt to assets
0.390.260.230.240.26
Net debt to EBITDA
8.9810.2410.96.184.54
Current ratio
3.134.95.655.665.21
Interest coverage
-45.33-56.86-47.08-65.04-65.96
Income quality
1.711.361.150.931.04
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.881.150.540.771.52
Research and developement to revenue
2.32.851.7536.55
Intangibles to total assets
0.010.010.0100
Capex to operating cash flow
000.010.010
Capex to revenue
-0.01-0.01-0.01-0.040
Capex to depreciation
-0.3-0.25-0.27-0.22-0.03
Stock based compensation to revenue
0.530.770.330.390.92
Graham number
1.71.851.592.52.01
ROIC
0.110.080.070.170.19
Return on tangible assets
-0.09-0.07-0.06-0.18-0.19
Graham Net
0.791.181.131.020.78
Working capital
123.14M202.78M189.72M161.42M132.36M
Tangible asset value
115.84M191.27M179.55M152.86M125.04M
Net current asset value
105.1M186.71M175.25M148.47M120.93M
Invested capital
0.160.10.10.120.13
Average receivables
4.68M5.04M3.61M2.19M3.22M
Average payables
16.2M13.15M13.92M17.08M19.61M
Average inventory
453K528K622K650.5K647.5K
Days sales outstanding
51.1268.0910.2221.7574.67
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
1.761.328.84.141.21
Payables turnover
00000
Inventory turnover
00000
ROE
-0.14-0.09-0.08-0.24-0.26
Capex per share
00000

AFMD Frequently Asked Questions

What is Affimed N.V. stock symbol ?

Affimed N.V. is a DE stock and trading under the symbol AFMD

What is Affimed N.V. stock quote today ?

Affimed N.V. stock price is $0.7192 today.

Is Affimed N.V. stock public?

Yes, Affimed N.V. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap